(Q44214910)

30 November 2017

title

Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration (English)

1 reference

30 November 2017

1 reference

Andrea L True

1

1 reference

30 November 2017

Yu-Yuan Chiu

2

1 reference

30 November 2017

Ralph A Demasi

3

1 reference

30 November 2017

Richard Stout

4

1 reference

30 November 2017

Indra Patel

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

30 November 2017

1 reference

30 November 2017

volume

26

1 reference

30 November 2017

issue

12

1 reference

30 November 2017

page(s)

1679-1686

1 reference

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Delivery of insulin by jet injection: recent observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.12.1679

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.12.1679

1 reference

30 November 2017

1 reference